Clinical trial
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
NCT02074059 is registered in ClinicalTrials.gov with Windtree Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
- Lead sponsor
- Windtree Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2014
- Completion date
- November 30, 2015
- Enrollment
- 80 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.